Estimands for overall survival in clinical trials with treatment switching in oncology. (3rd October 2021)

• Record Type: Journal Article
• Authors: Manitz, Juliane; Kan‐Dobrosky, Natalia; Buchner, Hannes; Casadebaig, Marie‐Laure; Degtyarev, Evgeny; Dey, Jyotirmoy; Haddad, Vincent; Jie, Fei; Martin, Emily; Mo, Mindy; Rufibach, Kaspar; Shentu, Yue; Stalbovskaya, Viktoriya; (Sammi) Tang, Rui; Yung, Godwin; Zhou, Jiangxiu
• Is Part Of: Pharmaceutical statistics. Volume 21:Number 1(2022)
• Page Start: 150
• Page End: 162
• Publication Date: 2021-10-03
• Subjects: cross‐over -- estimand -- ITT -- overall survival -- treatment switching; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.2158
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract: An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise definition of the inferential quantity of interest, that is, the estimand. This definition explicitly accounts for intercurrent events, such as switching to new anticancer therapies for the analysis of overall survival (OS), the gold standard in oncology. Traditionally, OS in confirmatory studies is analyzed using the intention‐to‐treat (ITT) approach comparing treatment groups as they were initially randomized regardless of whether treatment switching occurred and regardless of any subsequent therapy (treatment‐policy strategy). Regulatory authorities and other stakeholders often consider ITT results as most relevant. However, the respective estimand only yields a clinically meaningful comparison of two treatment arms if subsequent therapies are already approved and reflect clinical practice. We illustrate different scenarios where subsequent therapies are not yet approved drugs and thus do not reflect clinical practice. In such situations the hypothetical strategy could be more meaningful from patient's and prescriber's perspective. The cross‐industry Oncology Estimand Working Group (www.oncoestimand.org ) was initiated to foster a common understanding and consistent implementation of the estimand framework in oncology clinical trials. This paper summarizes the group's recommendations for appropriate estimands in the presence of treatment switching, one of the key intercurrent events in oncology clinical trials. We also discuss how different choices of estimands may impact study design, data collection, trial conduct, analysis, and interpretation.